Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-World Observational Study of Patients Treated with Evinacumab
jRCT1041250126Recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Open-label, single-arm trial of evinacumab in familial hypercholesterolemia (FH), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoints: Safety (adverse events incidence and severity) and LDL cholesterol change. Started Nov 2025; status: recruiting.
02
Drugs
evinacumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on jRCT1041250126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041250126.